MedTrace Logo

Sorafenib in Urothelium Cancer of Bladder

NCT01215266 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2011-09-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the use of Sorafenib additionally to gemcitabine and cisplatin in bladder cancer.

Conditions

Interventions

DRUG

Sorafenib

Day 3-21 2x2 800 mg(milligram) daily

DRUG

Placebo

Day 3-21 2x2 800 mg(milligram) daily

Sponsors & Collaborators

  • University Hospital, Essen

    collaborator OTHER

  • Association of Urologic Oncology (AUO)

    lead OTHER

Principal Investigators

  • Susanne Krege, Prof. Dr. · Universität Duisburg-Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215266 on ClinicalTrials.gov